# US 2024/0199623 A1 · SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS CFTR MODULATORS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199623 A1
- Document ID: US20240199623A1
- Status: Published application
- Kind: A1
- Application number: 18/488,925
- Filed: 2023-10-17
- Published: 2024-06-20
- Earliest claimed: 2020-10-23
- Assignees: Ildong Pharmaceutical Co., Ltd.
- Applicants: Ildong Pharmaceutical Co., Ltd.
- Inventors: Myongjae Lee; Changmok Oh; Dami Lim; Kyeong-a Kim; Seolhee Lee; Ilji Jeong; Jaeeun RYU; Jooyun Lee; Yearin Jun; Jinsun Kwon; Te-ik Sohn; Gunhee Kim; Jungho Kim; Jongmin Yoon; Jin Hee Lee; Hongchul Yoon; Jung Woo Lee; Joontae Park; Kyung Mi AN
- Web page: https://patentgrep.com/patent/US20240199623A1

## CPC

- A61P 27/02: Ophthalmic agents
- C07D 487/04: Ortho-condensed systems
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

CFTR modulator compounds and compositions including said compounds are provided. The present disclosure also provides PDE4 inhibiting compounds and compositions including said compounds. Also provided are methods of using said compounds and compositions for modulating CFTR, methods for treating an eye disease or disorder and methods for treating CFTR-related indications. The present disclosure also provides methods of using said compounds and compositions for inhibiting PDE4, for treating an inflammatory disease or disorder and for treating other PDE4-related indications. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.

## Claims

### Claim at position 1

1-80. (canceled)

### Claim 81

A compound of formula (Ia):
or a pharmaceutically acceptable salt, a solvate, a hydrate, a prodrug, or a stereoisomer thereof, wherein:
R1 is selected from H, halogen, optionally substituted aryl, optionally substituted (C1-C10)alkyl, and optionally substituted (C1-C10)alkoxy;
R2 is selected from H, optionally substituted (C1-C10) alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycle, and the optional substituents on aryl, heteroaryl, and heterocycle are independently selected from: H, OH, NH2, NO2, OCF3, CF3, halogen, optionally substituted amino, optionally substituted (C1-C5)alkyl, and optionally substituted (C1-C5)alkoxy;
R4 is selected from
R5 and R6 are independently selected from H, optionally substituted (C1-C10)alkyl, optionally substituted (C1-C10)alkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted monocyclic or bicyclic carbocycle, and optionally substituted monocyclic or bicyclic heterocycle;
or R5 and R6 together with the nitrogen atom to which they are attached are cyclically linked to form an optionally substituted monocyclic or bicyclic heterocycle, with the proviso that the monocyclic heterocycle is not piperazin-1-yl;
R7 is selected from NR5R6, optionally substituted (C1-C10)alkyl, optionally substituted (C1-C10)alkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;
R8 is selected from H and optionally substituted (C1-C10)alkyl; and
R9 is selected from H and halogen.

### Claim 82 (depends on 81)

The compound of claim 81, wherein the compound is of formula (Ib):
wherein:
X1 is CR10′ or N;
R1b is selected from H, halogen, optionally substituted aryl, optionally substituted (C1-C10)alkyl, and optionally substituted (C1-C10)alkoxy;
R4b is selected from
R5 and R6 are independently selected from H, optionally substituted (C1-C10)alkyl, optionally substituted (C1-C10)alkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted monocyclic or bicyclic carbocycle, and optionally substituted monocyclic or bicyclic heterocycle;
or R5 and R6 together with the nitrogen atom to which they are attached are cyclically linked to form an optionally substituted monocyclic or bicyclic heterocycle, with proviso that the monocyclic heterocycle is not piperazin-1-yl;
R7 is selected from NR5R6, optionally substituted (C1-C10)alkyl, optionally substituted (C1-C10)alkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;
R8 is selected from H and optionally substituted (C1-C10)alkyl;
R9b is selected from H and halogen;
each R10 and R10′ is independently selected from H, OH, NH2, NO2, halogen, optionally substituted (C1-C6)alkyl, optionally substituted (C1-C6)alkoxy, and substituted amino; and
n is 0 to 4.

### Claim 83 (depends on 82)

The compound of claim 82, wherein the compound is of formula (Ic):
wherein:
X2 is CR10c′ or N;
R21 is selected from H, and optionally substituted (C1-C10)alkyl; optionally substituted acyl; optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted monocyclic or bicyclic carbocycle, and optionally substituted monocyclic or bicyclic heterocycle;
R1c is selected from H, halogen, optionally substituted aryl, optionally substituted (C1-C10)alkyl, and optionally substituted (C1-C10)alkoxy;
R4c is selected from
R5 and R6 are independently selected from H, optionally substituted (C1-C10)alkyl, optionally substituted (C1-C10)alkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted monocyclic or bicyclic carbocycle, and optionally substituted monocyclic or bicyclic heterocycle; or R5 and R6 together with the nitrogen atom to which they are attached are cyclically linked to form an optionally substituted monocyclic or bicyclic heterocycle, with proviso that the monocyclic heterocycle is not piperazin-1-yl;
R7 is selected from NR5R6, optionally substituted (C1-C10)alkyl, optionally substituted (C1-C10)alkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;
R8 is selected from H and optionally substituted (C1-C10)alkyl;
R9c is selected from H and halogen;
each R10c and R10c′ is independently selected from H, OH, NH2, NO2, halogen, optionally substituted (C1-C6)alkyl, optionally substituted (C1-C6)alkoxy, and substituted amino; and
n is 0 to 3.

### Claim 84 (depends on 83)

The compound of claim 83, wherein the compound is of formula (Id):
wherein:
X3 is CR10d′ or N;
each R21d is independently selected from H, and optionally substituted (C1-C10)alkyl;
optionally substituted acyl; optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted monocyclic or bicyclic carbocycle, and optionally substituted monocyclic or bicyclic heterocycle;
R1d is selected from H, halogen, optionally substituted aryl, optionally substituted (C1-C10)alkyl, and optionally substituted (C1-C10)alkoxy;
R4d is selected from
R5 and R6 are independently selected from H, optionally substituted (C1-C10)alkyl, optionally substituted (C1-C10)alkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted monocyclic or bicyclic carbocycle, and optionally substituted monocyclic or bicyclic heterocycle;
or R5 and R6 together with the nitrogen atom to which they are attached are cyclically linked to form an optionally substituted monocyclic or bicyclic heterocycle, with proviso that the monocyclic heterocycle is not piperazin-1-yl;
R7 is selected from NR5R6, optionally substituted (C1-C10)alkyl, optionally substituted (C1-C10)alkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;
R8 is selected from H and optionally substituted (C1-C10)alkyl;
R9d is selected from H and halogen;
each R10d and R10d′ is independently selected from H, OH, NH2, NO2, halogen, optionally substituted (C1-C6)alkyl, optionally substituted (C1-C6)alkoxy, and substituted amino; and
n is 0 to 2.

### Claim 85 (depends on 81)

The compound of claim 81, wherein R4 is
wherein:
ring A is an optionally substituted monocyclic or bicyclic (C4-C10)heterocycle;
Z1 is CR14 or N, where R14 is selected from H, OH, NH2, CN, CF3, OCF3, CH2NH2, halogen, optionally substituted (C1-C5)alkyl, optionally substituted (C1-C5)alkoxy, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted carbocycle, and optionally substituted heterocycle, wherein when Z1 is N, ring A is optionally substituted bicyclic (C4-C10)heterocycle; and
R16 is selected from H, halogen, —OR22a, —C(O)R22b, —CO2R22c, and —C(O)NR50R60, —NR50R60, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted (C1-C5)alkyl, and optionally substituted (C1-C5)alkoxy;
R22a, R22b, and R22c are independently selected from H, optionally substituted (C1-C10) alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycle; and
R50 and R60 are independently selected from H, optionally substituted (C1-C10)alkyl, optionally substituted (C1-C10)alkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted monocyclic or bicyclic carbocycle, and optionally substituted monocyclic or bicyclic heterocycle;
or R50 and R60 together with the nitrogen atom to which they are attached are cyclically linked to form an optionally substituted heterocycle, or an optionally substituted heteroaryl.

### Claim 86 (depends on 85)

The compound of claim 85, wherein the A ring is an optionally substituted piperidine, pyrrolidine, or azetidine, and wherein when the A ring is optionally substituted piperidine, then R16 comprises at least one cyclic group selected from optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocycle, optionally substituted heterocycle.

### Claim 87 (depends on 85)

The compound of claim 85, wherein the A ring is:
wherein:
one or both of R23-R24 and R25-R26 together with the carbon atom to which they are attached are cyclically linked to form an optionally substituted carbocycle or an optionally substituted heterocycle;
the others of R23-R26 are each independently selected from H, halogen, OH, NO2, OCF3, CF3, optionally substituted amino, optionally substituted (C1-C6)alkyl, optionally substituted (C1-C6)alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycle; and
R40a and R40b are each independently selected from H, halogen, OH, NO2, OCF3, CF3, optionally substituted amino, optionally substituted (C1-C6)alkyl, optionally substituted (C1-C6)alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycle.

### Claim 88 (depends on 85)

The compound of claim 85, wherein R16 is:
—(R110)nR210
wherein:
each R110 is independently selected from optionally substituted (C1-C6)alkyl,
—C(O)(R110a)n1, —C(O)O(R110b)n2, —S(O)(R110c)n3, —SO2(R110d)n4, and —C(O)NR27(R110e)n5; where R110a-R110e are each independently optionally substituted (C1-C6)alkyl,
R27-R28 are each independently selected from H and optionally substituted (C1-C6)alkyl; and n-n5 are each independently 0 to 3; and
R210 is selected from optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocycle and optionally substituted heterocycle.

### Claim 89 (depends on 88)

The compound of claim 88, wherein R210 is selected from:
wherein:
X4-X7, X9, and X11 are each independently selected from CH, CR31, S, O, and N;
X8, X10, X12 and X13 are each independently selected from S, O, and NR29;
R29 is selected from H and optionally substituted (C1-C6)alkyl;
R30-R32 are each independently selected from H, halogen, OH, NO2, OCF3, CF3, optionally substituted amino, optionally substituted (C1-C6)alkyl, optionally substituted (C1-C6)alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycle; and
m1-m2 are each independently 0 to 5.

### Claim 90 (depends on 85)

The compound of claim 85, wherein R4 is selected from:

### Claim 91 (depends on 81)

The compound of claim 81, wherein R5 is H or Me, and R6 is selected from:
wherein:
Y1, Y2, and Y3 are independently selected from CR14 and N;
Z is selected from O, S, CHR11, and NR12;
n is 0 to 4;
R11 is selected from H, NH2, CN, CH2NH2, NO2, halogen, OR2a, C(O)R2b, CO2R2c, C(O)NR5R6, optionally substituted amino, optionally substituted (C1-C5)alkyl, and optionally substituted (C1-C5)alkoxy, and optionally substituted heterocycle;
R12 is selected from H, NH2, halogen, C(O)R2d, CO2R2e, C(O)NR5R6, and optionally substituted (C1-C5)alkyl;
is selected from optionally substituted (C1-C6)alkyl-cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted monocyclic or bicyclic (C4-C10)carbocycle, and optionally substituted monocyclic or bicyclic (C4-C10)heterocycle;
R13 is selected from H, NH2, CN, CH2NH2, NO2, halogen, OR2, C(O)R2g, CO2R2h, C(O)NR5R6, NR5R6, NHC(O)R2, optionally substituted (C1-C5)alkyl, and optionally substituted (C1-C5)alkoxy, and optionally substituted heterocycle;
R14 is selected from H, OH, NH2, CN, CF3, OCF3, CH2NH2, halogen, CO2R2, C(O)NR5R6, optionally substituted (C1-C5)alkyl, optionally substituted (C1-C5)alkoxy, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted carbocycle, and optionally substituted heterocycle;
R15 is selected from H, halogen, NHC(O)R2i, OR2j, C(O)R2k, OC(O)R2l CO2R2m, C(O)NR5R6, NR5R6 optionally substituted (C1-C5)alkyl, optionally substituted (C1-C5)alkoxy, optionally substituted cycloalkyl, and optionally substituted heterocycle;
R20 is selected from H, halogen, optionally substituted (C1-C5)alkyl, optionally substituted (C1-C5)alkoxy, optionally substituted carbocycle, and optionally substituted heterocycle; and
R2a-R2m are independently selected from H, optionally substituted (C1-C10) alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycle, and the optional substituents on alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle are independently selected from: H, OH, NH2, NO2, OCF3, CF3, halogen, heterocycle, heteroaryl, optionally substituted amino, optionally substituted (C1-C5)alkyl, and optionally substituted (C1-C5)alkoxy.

### Claim 92 (depends on 91)

The compound of claim 91, wherein R6 is selected from:
wherein:
ring B and ring C are each independently selected from optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocycle and optionally substituted heterocycle;
each R111 is independently selected from optionally substituted (C1-C6)alkyl
—C(O)(R111a)p1, —C(O)O(R111b)p2, —S(O)(R111c)p3, —SO2(R111d)p4, and —C(O)NR27(R111e)p5; where R111a-R111e are each independently optionally substituted (C1-C6)alkyl,
R27-R28 are each independently selected from H and optionally substituted (C1-C6)alkyl; and
p-p5 are each independently 0 to 3.

### Claim 93 (depends on 91)

The compound of claim 91, wherein R6 is
and is selected from:

### Claim 94 (depends on 93)

The compound of claim 93, wherein R13 is selected from:

### Claim 95 (depends on 91)

The compound of claim 91, wherein R6 is selected from:

### Claim 96 (depends on 81)

The compound of claim 81, wherein R5 is H or Me, and R6 is selected from:

### Claim 97 (depends on 81)

The compound of claim 81, wherein R7 is selected from optionally substituted N-anilino, optionally substituted phenyl and optionally substituted bicyclic carbocycle.

### Claim 98 (depends on 81)

The compound of claim 81, wherein:
when R1 and R9 are H, R4 is
R5 is H, and R6 is optionally substituted aryl; then R2 is not 4-fluoro-phenyl, p-toluene, 3,5-dichloro-phenyl, or phenyl; or
when R1 and R9 are H, and R4 is any one of the following:
then R2 is not 3,4-dimethoxy-phenyl.

### Claim 99 (depends on 81)

A pharmaceutical composition comprising:
a therapeutically effective amount of a compound according to claim 81.

### Claim 100 (depends on 99)

The pharmaceutical composition of claim 99, wherein the composition is an ophthalmic composition, and comprises a physiologically compatible ophthalmic vehicle.

### Claim 101 (depends on 1)

A method of modulating CFTR, the method comprising contacting a sample or biological system with an effective amount of a compound according to claim 1 to modulate the CFTR.

### Claim 102 (depends on 81)

A method of inhibiting PDE4, the method comprising contacting a sample or biological system with an effective amount of a PDE inhibiting compound according to claim 81.

### Claim 103 (depends on 81)

A method of treating dry eye disease, the method comprising administering to an eye of a subject a therapeutically effective amount of a compound according to claim 81.

### Claim 104 (depends on 81)

A method of treating an inflammatory disease, comprising administering to a subject a therapeutically effective amount compound according to claim 81.

### Claim 105 (depends on 104)

The method of claim 104, wherein the inflammatory disease is selected from chronic obstructive pulmonary disease (COPD), asthma, inflammatory airway disease, psoriasis, psoriatic disorder, atopic dermatitis, inflammatory bowel disease (IBD), rheumatoid arthritis, ankylosing spondylitis, neuroinflammation, and conjunctivitis.

### Claim 106 (depends on 81)

A method of treating a CFTR-related indication, comprising administering to a subject in need thereof a therapeutically effective amount of compound according to claim 81 wherein the CFTR-related indication is selected from chronic obstructive pulmonary disease (COPD), asthma, bronchitis, bronchiectasis, celiac disease, constipation, cholestatic liver disease, chronic rhinosinusitis, and hepatic impairment.
